Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants

Copyright © 2021. Published by Elsevier Ltd..

COVID-19 pandemic has severely impacted the public health and social economy worldwide. A safe, effective, and affordable vaccine against SARS-CoV-2 infections/diseases is urgently needed. We have been developing a recombinant vaccine based on a prefusion-stabilized spike trimer of SARS-CoV-2 and formulated with aluminium hydroxide and CpG 7909. The spike protein was expressed in Chinese hamster ovary (CHO) cells, purified, and prepared as a stable formulation with the dual adjuvant. Immunogenicity studies showed that candidate vaccines elicited robust neutralizing antibody responses and substantial CD4+ T cell responses in both mice and non-human primates. And vaccine-induced neutralizing antibodies persisted at high level for at least 6 months. Challenge studies demonstrated that candidate vaccine reduced the viral loads and inflammation in the lungs of SARS-CoV-2 infected golden Syrian hamsters significantly. In addition, the vaccine-induced antibodies showed cross-neutralization activity against B.1.1.7 and B.1.351 variants. These data suggest candidate vaccine is efficacious in preventing SARS-CoV-2 infections and associated pneumonia, thereby justifying ongoing phase I/II clinical studies in China (NCT04982068 and NCT04990544).

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:39

Enthalten in:

Vaccine - 39(2021), 48 vom: 26. Nov., Seite 7001-7011

Sprache:

Englisch

Beteiligte Personen:

Liu, Haitao [VerfasserIn]
Zhou, Chenliang [VerfasserIn]
An, Jiao [VerfasserIn]
Song, Yujiao [VerfasserIn]
Yu, Pin [VerfasserIn]
Li, Jiadai [VerfasserIn]
Gu, Chenjian [VerfasserIn]
Hu, Dongdong [VerfasserIn]
Jiang, Yuanxiang [VerfasserIn]
Zhang, Lingli [VerfasserIn]
Huang, Chuanqi [VerfasserIn]
Zhang, Chao [VerfasserIn]
Yang, Yunqi [VerfasserIn]
Zhu, Qianjun [VerfasserIn]
Wang, Dekui [VerfasserIn]
Liu, Yuqiang [VerfasserIn]
Miao, Chenyang [VerfasserIn]
Cao, Xiayao [VerfasserIn]
Ding, Longfei [VerfasserIn]
Zhu, Yuanfei [VerfasserIn]
Zhu, Hua [VerfasserIn]
Bao, Linlin [VerfasserIn]
Zhou, Lingyun [VerfasserIn]
Yan, Huan [VerfasserIn]
Fan, Jiang [VerfasserIn]
Xu, Jianqing [VerfasserIn]
Hu, Zhongyu [VerfasserIn]
Xie, Youhua [VerfasserIn]
Liu, Jiangning [VerfasserIn]
Liu, Ge [VerfasserIn]

Links:

Volltext

Themen:

34S289N54E
5QB0T2IUN0
Alum Compounds
Aluminum Hydroxide
Aluminum sulfate
Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
Journal Article
Research Support, Non-U.S. Gov't
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Subunit vaccine
Trimeric spike protein

Anmerkungen:

Date Completed 26.11.2021

Date Revised 29.11.2021

published: Print-Electronic

ClinicalTrials.gov: NCT04982068, NCT04990544

Citation Status MEDLINE

doi:

10.1016/j.vaccine.2021.10.066

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM332880397